E
Editas Medicine
Unlocking the promise of genome editing to deliver life-changing medicines
Latest news
Press, funding announcements and product moves mentioning Editas Medicine.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Juno Therapeutics
Flagship Pioneering
Polaris Partners
Third Rock Ventures- PFPartners Innovation Fund
Series B and later12 investors entered at this stage
- ECEcoR1 Capital
Casdin Capital- VIViking Global Investors
- OFOmega Funds
T. Rowe Price- HUHarvard University
- AIAlexandria Venture Investments
Khosla Ventures- JAJennison Associates
Fidelity Investments- DEDeerfield
- BNBoris Nikolic
Source: Dealroom Talent Intelligence.
Alumni founders
Former Editas Medicine employees who went on to found companies, sorted by Dealroom signal score.
KTKate TherapeuticsEst. 2020
Sharif TabebordbarUnited States
BTBeam TherapeuticsEst. 2017
PAPairwiseEst. 2017
David LiuUnited States
GBGate BioscienceEst. 2021
MBMammoth BiosciencesEst. 2017
Jennifer A. DoudnaUnited StatesGlobal footprint
team presence
across markets
Patents
71 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Editas Medicine on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Editas Medicine on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.